Aberrant DNA hypermethylation in human cancer has been associated with Polycomb target genes in embryonic stem (ES) cells, but a functional link of the Polycomb-targeted differentiation program to tumorigenesis remains to be established. Here, through epigenome analysis correlating DNA hypermethylation in colon cancer with ES cell pluripotency and differentiation, we identified a set of DNA hypermethylated genes in cancer cells that are Polycomb targets strongly associated with ES cell differentiation, including HAND1, a developmental regulator. Intriguingly, HAND1 is silenced in over 90% of human primary colorectal tumors, and re-expression of HAND1 in colon cancer cells induces terminal differentiation, inhibits proliferation and prevents xenograft tumor formation. Moreover, hypermethylated HAND1 has a minimum enrichment of EZH2-H3K27me3 in cancer cells, but becomes EZH2 bound and bivalent upon the loss of DNA methylation, suggesting a sequential gene silencing event during oncogenesis. These findings established a functional role of Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in human cancer.
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In addition to well-documented DNA hypermethylation, Polycomb-based epigenetic mechanisms are also emerging as new factors in tumorigenesis. The Polycomb group (PcG) protein EZH2 is a histone methyltransferase specific for histone H3 lysine trimethylation (H3K27me3) 1 and its deregulation has been found frequently in aggressive human cancer. [2] [3] [4] Although Polycomb-mediated gene repression is traditionally associated with early stage differentiation/development, evidence supporting EZH2 or H3K27me3-mediated gene silencing as a critical cancer-relevant epigenetic event is rapidly emerging. To date, several EZH2 target genes have been functionally linked to various cancer pathways, [5] [6] [7] [8] further supporting its role in tumorigenesis. Currently, there is growing interest in defining the functional relationship between repressive histone modifications and DNA methylation in cancer development. Technological advances in highresolution, genome-wide mapping of histone modifications, such as chromatin immunoprecipitation (ChIP)-PET or ChIPseq, are now spurring systematic efforts to characterize epigenome modifications and their potential relationships. [9] [10] [11] [12] Loss of differentiation is an important component in the pathogenesis of many cancers. 13 It has been previously reported that many differentiation genes are transcriptionally repressed by Polycomb repressive complex 2 (PRC2) through bivalent chromatin modifications (carrying both H3K27me3 and H3K4me3 histone marks) to maintain the self-renewal features of embryonic stem (ES) cells. 14, 15 Moreover, genes silenced by DNA hypermethylation in adult human tumors have been found to be preferentially targeted by PRC2 in human ES cells. [16] [17] [18] Although these studies are provocative and suggest a possibility that the two gene silencing events may lead to inactivation of a differentiation/developmental program important for tumor surveillance, a functional link between Polycomb-targeted differentiation program with oncogenesis has not yet been established. Therefore, we aim to investigate the relationship between Polycombmediated histone modification and DNA methylation in cell differentiation and cancer development.
In this study, we performed integrative epigenome analysis in both human cancer cells and ES cells, and have identified a cancer gene silencing event associated with ES cell differentiation that is targeted by both DNA hypermethylation and Polycomb-mediated histone methylation in colon cancer cells. We further establish the critical role of the differentiation regulator HAND1, a key gene in this process, as a putative tumor suppressor epigenetically lost in colorectal cancer.
Results
Gene silencing associated with promoter DNA hypermethylation in colon cancer. As a first step to identify genes whose expression is affected by DNA hypermethylation, we compared the gene expression profiles of colorectal cancer line HCT116 with its counterpart HCT116-DKO in which both DNA methyltransfease 1 (DNMT1) and DNMT3B are genetically disrupted or HCT116 cells treated with DNA methylation inhibitor 5-Aza-2'-deoxycitidine (5-Aza-dC). Using the Illumina array, we have identified 1275 genes whose expression is upregulated (using threefold cutoff) in either condition (Figure 1a and Supplementary Table S1A ). Further profiling of these genes across a variety of colon cancer cell lines and normal colon epithelium identified a subset of 753 genes consistently repressed in the cancer cell lines (Supplementary Table  S1B ). To determine whether the above gene set identified in established cell lines are of clinical relevance, we compared their expression profiles in 24 pairs of clinical colon tumor samples matched to normal colon tissues. The cluster analysis revealed 476 out of these 753 genes showed a consistent and marked repression in tumors compared with the normal controls, pointing to a clinical relevance of this set of genes beyond just the initial cell lines studied (Figure 1a  and Supplementary Table S1C ). Among this 476 gene list are many genes previously reported to be silenced by DNA hypermethylation in colon cancer (e.g., SFRP1, CDH2, UCHL1 and ELOVL4) but it also included many genes previously not reported to be DNA hypermethylated.
Histone H3 lysine 4 trimethylation (H3K4me3) is associated with active gene promoter, 10, 19 with the majority of these marks located within 1.0 kb of transcription start sites (TSS). Moreover, H3K4me3 and DNA hypermethylation are mutually exclusive: DNMTs only recognize sites with unmethylated H3K4 20, 21 and loss or gain of H3K4 methylation is a strong predictor of promoter DNA methylation status. 12 As such, measuring the H3K4me3 status in our original HCT116 cells and the corresponding DNMT double knock out line would provide an independent measure of promoter activity (and DNA methylation status) to our expression Beadchips. Thus, we next generated genome-wide maps of H3K4me3 in both HCT116 and DKO cells by chromatin immunoprecipitation combined with high-throughput sequencing (ChIP-seq). A total of 11 747 and 13 074 high confidence H3K4me3 sites Table S2) .
To distinguish the most robust gene set that appeared to be silenced in colon cancer cells by DNA methylation, we next identified the overlapped genes between the 476 silenced genes identified by expression Beadchips and the 2075 genes bound by H3K4me3 ChIP-seq. These H3K4me3-negative and expression-negative genes in parental HCT116 cells consisted of 203 genes (Figure 1c and Supplementary Table  S3 ) and they are re-expressed in DKO cells with a gain of H3K4me3. For convenience, we define these genes as colon cancer methylation silenced (CMS) genes for the remainder of the paper. Figure 1d illustrates two CMS genes (SFRP1 and CDH2) to exemplify such changes in DNA methylation and H3K4me3 in HCT116 and DKO cells. We also randomly validated an additional set of CMS genes by RT-PCR and methylation-specific PCR (MSP) (see Supplementary Figures S1A and S1B). In each case, the gene was verified to be promoter methylated and silenced in HCT116 cells but became demethylated and re-expressed in DKO cells, validating the accuracy of this genomic approach.
Identification of CMS genes associated with ES cell differentiation. It has been reported that genes identified as having methylated promoters in cancer, in ES cells, contain repressive histone marks. [16] [17] [18] The expression of these PRC2 target genes is repressed in ES cells and only activated upon induction of differentiation. 15, 22 This link prompted us to investigate the possibility that our CMS genes may represent a set of genes involved in a differentiation program that is subsequently lost/repressed in human cancer. To determine if any of our CMS genes are repressed in human ES cells and activated upon differentiation, we examined gene expression in undifferentiated human ES cells to human ESCs induced to differentiate along the trophoblast lineage. In this differentiation system, hESC pluripotency regulators Oct4, Sox2 and Nanog are significantly downregulated within 96 h (Figure 2a and Supplementary Table S4 ) and markers of the trophoblast lineage (e.g., CDX2, GATA3, GATA2 and TFAP2A) are greatly upregulated (data not shown). Of 203 CMS genes, 40 were absent or detectable at very low levels in the undifferentiated human ES cells but were upregulated upon differentiation ( Figure 2a ). We next compared these gene lists with earlier studies including ours characterizing the bivalently marked genes (H3-K4me3 and H3-K27me3) in undifferentiated hESCs. 10, 22, 23 Of the 40 CMS genes identified to be upregulated upon differentiation of hESCs, 21 of these also contained the bivalent marks in undifferentatiated hESCs ( Figure 2b ). Among these 21 genes associated with ES cell differentiation, HAND1, a transcription factor involved in the regulation of development, showed the highest level of induction during differentiation ( Figure 2a ). Thus, of our initial 203 colon cancer DNA methylation repressed genes, 21 of these contain repressive histone marks in undifferentiated human ESCs and are subsequently activated upon differentiation. Of particular interest is HAND1, one of only two transcription factors in this 21 gene list and the most upregulated in the hESC differentiation system.
Removal of DNA methylation promotes EZH2 recruitment to a small set of CMS genes, including HAND1. We next wished to determine whether differentiation-associated CMS genes are also PcG targets in adult colon cancer cells. It has been previously shown that PRC2 protein EZH2 can directly control DNA methylation for gene Only genes with twofold or greater change in at least one time point during differentiation are shown. Self-renewing factors, OCT4, SOX2 and NANOG2, were included in this analysis as experimental control. The genes were rank ordered in terms of fold-changes. In total, 40 CMS genes were found to be associated with differentiation and 68 genes were found to be associated with self-renewal. Hand1 was ranked ordered as top CMS gene associated with differentiation. (b) Listed are 21 PRC2 target genes previously identified in ES cells silencing at certain gene promoters. 24 However, a recent genome-wide analysis of chromatin patterns in human breast and prostate cancer cells does not seem to support a mechanistic link between the two silencing events. 9 Moreover, a recent study in colon cancer cells suggests that removal of DNA methylation does in fact promote a gain of bivalency in methylated gene promoters. 11 Thus, the observed bivalency may be associated with enhanced EZH2 recruitment upon loss of DNA methylation in colon cancer cells.
To test this hypothesis, we generated genome-wide maps of EZH2 binding in both HCT116 and DKO cells. Of the 203 CMS genes identified above, only 20 genes (o 10%) were found to be bound by EZH2 in HCT116 cells (FDR 5%, within in 2.0 kb of TSS site) (data not shown). This finding is consistent with the recent genome-scale analysis showing DNA hypermethylated promoters are largely not marked by H3K27me3, 9 further confirming these two silencing events are mechanistically separable in colon cancer. In DKO cells, however, we detected 39 out of 203 CMS genes displaying a marked increase in EZH2 binding and 6 of these, including HAND1, were associated with differentiation in ES cells (Figure 3a) . We confirmed the EZH2 and H3K4me3 binding profiles in four of these genes (in addition to two control genes) by ChIP-PCR in both HCT116 and DKO cells. This showed a marked increase in enrichments of both EZH2 and H3K4me3 in DKO cells compared with HCT116 cells (Figure 3b) . As a control, CDH2 and SFRP1 were only weakly bound by EZH2 in both cell lines (Figure 3b ). These data indicate that, by enhanced recruitment of EZH2, a subset of CMS genes remain repressed in the DNA methylation-defective DKO cells (Figure 3c ), suggesting an additional mechanism to prevent their re-expression. By contrast, CMS genes that do not show an enhanced EZH2 binding in DKO cells (such as CDH1 and SFRP1) appear to be sufficiently re-expressed with an open chromatin carrying mainly H3K4me3 ( Figure 3b , right panel; and Figure 3c ).
To further illustrate the epigenetic events in detail, we chose to focus on HAND1. Both MSP and bisulfite sequencing analysis detected the hypermethylated DNA in the distal and immediate promoter regions of HAND1 in HCT116 but not in DKO cells (Figure 3d H3K4me3 and H3K27me3, clearly indicating a bivalent chromatin surrounding the TSS (Figure 3h) . Thus, the gain of this bivalency of HAND1 in DKO cells may be responsible for its remained repression in these cells.
Pharmacological reactivation of HAND1 in colon cancer cells. We have previously shown that histone methylation inhibitor Deazaneplanocin A (DZNep) is able to inhibit histone methylations, such as H3K27me3 and H4K20me3, and reverses EZH2-mediated gene silencing in cancer cells. 25 Moreover, genes silenced by bivalent histone modifications, such as DACT3 or CDKN1C, but not those silenced by DNA hypermethylation, are strongly reactivated by DZNep in combination with histone deacetylase inhibitor Trichostatin A (TSA). 6, 26 Accordingly, HAND1, whose expression was only slightly increased in DKO cells, was strongly induced by combined treatment of DZNep and TSA and this was not seen in the parental HCT116 cells (Figure 4a, left panel) . By contrast, the expression of SFRP1, which was not an EZH2 target and was already strongly reexpressed in DKO cells, was not further induced by such a combination treatment (Figure 4a, right panel) . ChIP analysis indicated a decreased recruitment of both EZH2 and H3K27me3 to HAND1 and a concomitant further increase in H3K4me3 in DKO cells treated with the DZNep/TSA combination but not in HCT116 cells (Figure 4b ). These findings suggest that HAND1 promoter demethylation in DKO cells is insufficient to give rise to a full HAND1 re-expression due to a gain of bivalent chromatin modifications but make it render to the DZNep/TSA treatment that is able to target bivalency. Consistently, pre-treatment of HCT116 cells with the DNA methylation inhibitor 5-Aza-dC, followed by DZNep/TSA treatment resulted in a much greater level of HAND1 induction, compared with treatment with 5-Aza-dC or DZNep/TSA alone (Figure 4c) . A similar result was also obtained in another colon cancer cell line DLD1 in which the HAND1 promoter was also found to be hypermethylated (Figures 4d and 3g) .
Unlike HCT116 and DLD1 cells, HAND1 in SW480 cells was found to be hypermethylated in a distal M1 region, but not in the immediate promoter region (M2) (Figure 3g) . In SW480 cells, HAND1 expression was strongly induced by DZNep/ TSA treatment (Figure 4e) . Accordingly, HAND1 in these cells was found to be bivalent and carries both H3K4me3 and H3K27me3, which was disrupted by DZNep/TSA (Figure 4f) , a result similar to DKO cells. Thus, HAND1 in colon cancer is silenced by either DNA methylation or Polycomb-mediated histone methylation or both, depending on the cell type.
Differentiation regulator HAND1 is silenced in multiple human malignancies. Among 40 CMS genes associated with ES differentiation, HAND1 ranks as the most downregulated in primary colon tumor samples compared with the normal controls in 90% of the primary colon tumors analyzed (Figure 5a ). This striking downregulation of HAND1 in colon cancer was further confirmed by RT-PCR analysis using randomly selected colon tumor samples and matched normal tissues (Figure 5b) , which was consistent with the hypermethylation of HAND1 promoter, as determined by MSP and bisulfite sequencing, in the primary colon tumors but not in the normal controls (Figures 5c and d) . In addition, Oncomine analysis revealed the downregulation of HAND1 in a variety of other human tumors, including bladder, brain and cervix (Figure 5e ), indicating that a loss of HAND1 expression may be involved in tumorigenesis of many cancers.
Restoration of HAND1 expression in colon cancer induces terminal differentiation, inhibits cell proliferation and prevents xenograft tumor formation. To investigate the function of HAND1 in colon cancer, we ectopically expressed HAND1 in colon cancer cell lines HCT116 and DLD1 (Supplementary Figure S2A) . Overexpression of HAND1 resulted in marked inhibition of colony formation (Figure 6a ) and anchorage-independent growth in soft agar (Figure 6b ). Ectopic HAND1 was also able to abolish the transformation of mouse embryonic fibroblast cells induced by Ras/E1A oncoproteins (Figure 6c ). These results supported a role of HAND1 in suppressing cancer cell growth and cellular transformation.
To further characterize HAND1 as a tumor suppressor, we generated a stable line of DLD1 expressing a doxycycline (Dox)-inducible HAND1 (Supplementary Figure S2B) . Induction of HAND1 expression resulted in marked inhibition of both proliferation and anchorage-independent growth (Figures 6d  and 6e) . Notably, HAND1-expressing DLD1 cells maintained in Dox progressively displayed morphological changes characteristic of differentiation, including giant cell phenotype, flat and elongated morphology and multinucleate formation, which was not seen in the control (Figure 6f ). In contract, another tumor-suppressor candidate THY1, whose expression was also silenced by DNA methylation in colon cancer cells (Supplementary Table S1 ), did not induce such morphological changes, despite the proliferation inhibition (Supplementary Figures S2C-F) . Moreover, DLD1 cells expressing HAND1 lost proliferation over time, by measuring the proportion of cells in S phase with incorporation of bromodeoxyuridine (BrdU), which was concomitant with marked accumulation of tetraploid cells (Figure 6g ) and multinucleate formation observed under microscopy. Of note, the above phenotype induced by HAND1 in colon cancer cells resembles its established role in promoting mouse trophoblast stem cell differentiation toward giant cells undergoing endoreduplication. [27] [28] [29] Ultimately, prolonged exposure of HAND1-expressing DLD1 cells to Dox for over 2 weeks led to massive apoptosis upon detachment from matrix, as indicated by marked activation of caspase-3 ( Figure 6h ).
Next, we investigated the effect of HAND1 in vivo. DLD1 cells expressing GFP-GFP-HAND1 exhibited a similar morphological change of terminal differentiation (Supplementary Figure S3) . Although the control cells expressing GFP only developed subcutaneous tumors progressively (8 out of 8 inoculations), cells expressing GFP-HAND1 did not (0 out of 8 inoculations) (Figure 6i) . Thus, HAND1 functions as a tumor suppressor with a remarkable ability to disrupt cancer To investigate the molecular mechanism by which HAND1 induces growth inhibition and differentiation, we compared the gene expression profiles of DLD1 GFP and DLD1 GFP-HAND1, and identified 145 genes (using threefold cutoff) as induced by HAND1 (Supplementary Table S5 ). As expected, these genes were also found to be downregulated in colon tumors, as shown through the Gene set enrichment analysis (GSEA) (Figure 7a ).
Among HAND1-associated genes, we identified DHRS9 as the most induced gene (210-fold induction; Figure 7b ). DHRS9 encodes a retinol-metabolizing enzyme (retinol dehydrogenase) functionally implicated in retinoid-induced colon epithelial cell differentiation, 30, 31 and is downregulated in less differentiated colon carcinomas. 30, 32 Indeed, we found that DHRS9 was consistently downregulated in colon tumors (Figure 7c ). In addition, ectopic HAND1 was able to activate the DHRS9 promoter activity (Figure 7d) , indicating DHRS9 as a transcriptional target of HAND1. Like HAND1, DHRS9 overexpression in DLD1 cells was able to reduce both the anchorage-dependent and -independent growth of these cells (Figures 7e and f) . These findings suggest that tumor suppression function of HAND1 may be at least partially mediated through DHRS9.
Discussion
Although PRC2 is implicated in ES cell maintenance by repressing differentiation-associated genes 22, 33 and some of these genes are targeted by DNA hypermethylation for gene silencing during oncogenesis, [16] [17] [18] a functional link between genes important in (ES) cell differentiation and tumorigenesis yet to be established. In this study, we identify a Polycombtargeted differentiation program transcriptionally inactivated in human colorectal cancer and show that restoration of a key component of this program, HAND1, is able to induce colon cancer cell terminal differentiation and apoptosis. Thus, we propose that a HAND1-associated differentiation program acts to limit cancer development and thus by extension, provides a functional link between gene silencing, maintenance of proliferation, repressed differentiation by PRC2, in the context of tumorigenesis. Our study provides the first detailed description of temporal, bivalent DNA methylation and Polycomb silencing of a known (ES cell) differentiation gene in the context of tumor differentiation and progression.
A previous study suggests a similarity between the transcriptional signatures of poorly differentiated tumors to that of ES cells and this similarity extends to PRC2 target genes. 34 Although DNA methylation events in cancer have recently been suggested to be linked to a Polycomb-impeded differentiation program, a fundamental issue that remains unresolved is the mechanism by which the developmental program is inactivated during cancer initiation and development and whether it has a tumor-suppressor role. Our work here suggests that the mechanism involves epigenetic regulation of specific developmental regulatory genes, genes that are switched off and associated with repressive histone marks in ES cells, activated upon differentiation, but inactivated in adult cancer cells. More precisely, we found that the bivalency of a Polycomb target gene identified in ES cells, HAND1, is lost during cancer progression through the acquisition of promoter DNA hypermethylation resulting in gene silencing. This observation is consistent with the recent proposal that cancers arise from tumor-initiating stem cells that may share similar epigenetic properties with ES cells. [34] [35] [36] Although genes silenced by DNA hypermethylation in colon cancer have been well documented previously by several labs, [37] [38] [39] [40] the main aim of our study is to functionally investigate its relationship with EZH2-mediated H3K27me3 in the context of cell differentiation and cancer development. Our data suggest a mutually exclusive nature of EZH2 binding with DNA methylation in at least some of the DNA methylated genes. This observation is in agreement with several recent reports indicating the two silencing pathways are largely independent, 6, 9, 25 although this contrasts with a previous report showing that EZH2 directly controls DNA methylation. 24 It is also consistent with the previous observation that inhibition of DNA methylation facilitates the formation of bivalency and hence increasing the efficiency of reprogramming to a pluripotent state. 12 This information is critical in designing epigenetic therapy as distinct pharmacologic approaches are required to target these two separate pathways. 6, 25 At the mechanistic level, we show that EZH2 and H3K27me3 are minimally enriched in the hypermethylated HAND1 promoter, but their enrichments are increased when the promoter becomes demethylated. Similarly, HAND1 is also a Polycomb and H3K27me target in human ES cells where its promoter is unmethylated. 10 This reversibility may suggest a model in which the two silencing events may participate in HAND1 inactivation in different stages of colon tumorigenesis. Although a previous study shows that HAND1 promoter in colon cancer carries both PRC2 and DNA methylation, 41 it did not address the role of PRC2 and H3K27me3 in regulating HAND1 expression both before and after promoter demethylation. In fact, our result shows that HAND1 promoter demethylation is insufficient to fully reactivate HAND1 expression because of enhanced engagement of PRC2, resulting in a bivalent histone methylations, which, however, is sensitive to the combination treatment of histone modifying compounds DZNep and TSA. We speculate that many cancer genes carrying bivalent epigenetic configuration such as HAND1 may be susceptible to the pharmacologic perturbation with combinatorial epigenetic treatment as described herein. The hESC cell line WA01 (WiCell H1) was maintained in feeder-free conditions. Media containing 80% DMEM/F12 (Gibco, Grand Island, NY, USA) supplemented with 20% KNOCKED OUT serum replacement (Gibco), 1 mM L-glutamine (Gibco), 0.1 mM nonessential amino acids (Gibco) and 0.1 mM b-mercaptoethanol (Sigma) were conditioned on inactivated mouse embryonic fibroblasts and subsequently supplemented with 8 ng/ml FGF2 (Invitrogen, Grand Island, NY, USA) before use in hESC culture. hESC were induced to differentiate along the trophoblast lineage by a combined treatment of 100 ng/ml BMP4 (R&D Systems, Minneapolis, MN, USA) and 20 mM SU5402 (Calbiochem, San Diego, CA, USA).
Expression vectors and stable cell lines. HAND1 ORF was PCR amplified from normal colon tissue cDNA and was first subcloned into p3 Â FLAG-CMV10 and then into pcDNA4/myc-hisB (Invitrogen) for transient transfection and pcDNA4/TO/Flag-HAND1 for inducible expression. Retroviral-mediated gene transfer was performed using pMN-GFP/IRES retrovirus vector-expressing Hand1. Infected DLD1 cells were sorted by GFP signals and expanded for in vitro and in vivo studies. To generate the Hand1-inducible cell line, DLD1 stable cell line expressing pcDNA6-TR (Invitrogen) and selected with Blasticidin (10 mg/ml) was first isolated according to the protocols of T-Rex system kit (Invitrogen), and then transfected with the pcDNA4/TO/Flag-HAND1 and selected for Zeocin (100 mg/ml). The generated clones were screened for Dox-inducible expression of Flag-HAND1. For Dox treatment, inducible cells were treated with Dox to a final concentration of 1 mg/ml.
Microarray gene expression analysis, semiquantitative RT-PCR and Taqman assay. Total RNA was isolated using Trizol (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). Reverse transcription was performed using an RNA Amplification kit (Ambion, Grand Island, NY, USA). The microarray hybridization was performed using the Illumina Gene Expression Sentrix BeadChip HumanRef-8_V2, and data analysis was performed using GeneSpring software from Agilent Technologies (Santa Clara, CA, USA) as described. 6 For RT-PCR, total RNA was reverse-transcribed using oligo(dT)12-18 primer with Superscript II reverse transcriptase (Invitrogen). One hundred nanograms of cDNA was used for PCR and the primer sequences are shown in Supplementary Table 6 . Quantitative real-time PCR was performed on a PRISM 7900 Sequence Detection System (Applied Biosystems, Grand Island, NY, USA) using TaqMan probes (Applied Biosystems). Samples were normalized to the levels of GAPDH mRNA. GSEA of gene expression levels were analyzed with the GSEA2.0 software package (http://broad.mit.edu/tools/software.html).
DNA methylation analysis. The CpG island DNA methylation status was determined by PCR analysis after bisulfite modification of genomic DNA and followed by MSP and bisulfite genomic sequencing as previously described.
ChIP assays. ChIP assays were performed as described previously. 6 The immunoprecipitated DNA was quantitated by real-time quantitative PCR using Applied Biosystems 7900HT Fast Real-Time PCR System (Applied Biosystems). We used the following antibodies in the ChIP study: anti-H3K27m3 (Upstate, Lake Placid, NY, USA), anti-H3K4me3 (Upstate) and anti-EZH2 (Active-motif, Carlsbad, CA, USA). The enrichments of these histone marks at the examined regions were normalized to a genome control region. 6, 42 The sequences of the primer sets are shown in Supplementary Table 8 .
Luciferase reporter assay. Genomic DNA containing the human DHRS9 promoter regions À 1989/ À 950 and À 1061/ þ 451 were cloned into pGL3-luciferase construct (Promega, Madison, WI, USA). Luciferase assays were performed using the Dual Luciferase system (Promega). HCT116 cells were plated at a density of 3 Â 10 5 cells per well of a 12-well plate and transfected with a mixture containing luciferase reporter plasmid, HAND1 expression vector. Forty-eight hours after transfection, the luciferase activities were analyzed using the Dual Luciferase system. ChIP-seq. Purified immunoprecipitated DNA was prepared for sequencing according to a modified version of the solexa Genomic DNA protocol. Fragmented DNA was end paired and subjected to 15 cycle of linker-mediated-PCR using Oligos purchased from Illumina (San Diego, CA, USA). Amplified fragments between 200 and 300 bp were isolated by agarose gel electrophoresis and purified. The fragment DNA size was confirmed by Agilent DNA chip analysis. Ten nanograms of linker-ligated DNA was applied to the flow cell using the Solexa Cluster Station fluidics device (Illumina). Samples were then subjected to 36 bases of sequencing according to Illumina's standard protocols. The data generated from Solexa Genome Analyzer instrument underwent ChIP-seq pipeline, managed by the Research Computing group.
Cell proliferation assay, apoptosis and flow cytometric analysis. Cell growth was measured with CellTiter-Glo Luminescent Cell Viability Assay (Promega). In brief, 1000 cells were seeded in 96-well plate and the cell number was measured following the manufacturer's instructions. To measure caspase-3 activity, cells were harvested and fixed with Cytofix/ Cytoperm solution (BD Biosciences, Franklin Lakes, NJ, USA) as instructed after treatment with Dox for 9 days and then stained with fluorescein isothiocyanateconjugated rabbit anti-active caspase-3 monoclonal antibody (BD Biosciences). Quantification of cells positive for the caspase-3 was performed by flow cytometry.
For BrdU incorporation assay, cells were treated as above and incubated with BrdU reagent for 6 h before harvesting cells. Cells were fixed and stained with the BrdU antibody and 7-AAD according to the manufacturer's protocol (BD Biosciences). Stained cells were analyzed by FACScalibur (BD Biosciences) and quantified by using CellQuest software (BD Biosciences).
Colony formation and soft-agar assay. Cells were plated at 3.0 Â 10 5 per well using six-well plates, and transfected with either pcDNA4-HAND1 or empty vector (2.0 mg) using Fugen 6 (Roche, Indianapolis, IN, USA). The cells were replated in triplicates and cultured for 10-15 days in complete DMEM medium containing Zeocin (100 mg/ml) and stained with Gentian Violet after methanol fixation. For anchorage-independent growth, cells were transfected as above, and suspended in DMEM containing 0.3% agar, 10% fetal bovine serum, and layered on DMEM containing 0.6% agar, 10% FBS and Zeocin (100 mg/ml) in six-well plate at 48 h post-transfection. Colony formation was assessed at 4 weeks post-transfection.
Tumors and animal models. Eight female athymic BALB/c nude mice (5-to 8-week-old) were housed in the Biological Resource Centre. Mice were implanted subcutaneously in both sides of flank with 5 Â 10 5 of human colon cancer DLD1 cells infected with either pMN-GFP-HAND1 construct or empty pMN-GFP retroviral vector, respectively. Tumor progression was monitored by wholebody GFP imaging by using Olympus OV100 Small Animal Imaging System (Shinjuku-ku, Tokyo, Japan). All mouse procedures were pre-approved by the Institutional Animal Care and Use Committee (Singapore) and performed according to institutional policies.
